Onconetix Navigates Nasdaq Compliance and Strategic Acquisition Talks

Onconetix Inc. Charts Course in Men’s Health and Oncology

Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of therapeutics, diagnostics, and services in oncology and men’s health. The company’s lead products include Entadfi®, an FDA-approved, once-daily oral combination of finasteride and tadalafil for benign prostatic hyperplasia (BPH), and Proclarix®, an in vitro diagnostic test aimed at improving prostate cancer screening in men with indeterminate prostate-specific antigen (PSA) results.

Corporate Structure and Governance

Following shareholder approval on May 30, 2025, Onconetix implemented a 1-for-85 reverse stock split effective at 12:01 a.m. Eastern Time on June 13, 2025. This action reduced the number of outstanding shares from approximately 44.4 million to about 521,863, with fractional shares compensated in cash. Each share carries a par value of $0.00001. In a Schedule 13D/A filed on July 16, 2025, Altos Venture AG reported beneficial ownership of 273,230 shares, representing 35.8% of the total post-split shares. The company does not have a dividend policy and is governed by a board of directors that approved the split to comply with Nasdaq’s minimum bid-price requirement of $1.00 per share. On July 24, 2025, Onconetix announced the appointment of an executive to its leadership team, indicating an emphasis on experienced management and participation in industry events such as the ABFO National Conference.

Oncology by Ben Hershey

Recent Developments and News

• On April 8, 2025, Onconetix and Ocuvex Therapeutics, Inc. entered into a non-binding Letter of Intent for a potential business combination. Under the proposed terms, Onconetix would acquire all outstanding equity of Ocuvex, an ophthalmic biopharmaceutical company with FDA-approved products and late-stage clinical assets, in exchange for newly issued Onconetix common shares. Upon closing, Ocuvex equity holders would own approximately 90% of Onconetix shares. Completion is subject to due diligence, financing, regulatory, and stockholder approvals.

• On April 18, 2025, Nasdaq staff issued a notice to Onconetix regarding non-compliance with the minimum bid-price requirement. A second notice was issued on April 24, 2025, for failure to file its Annual Report on Form 10-K for the fiscal year ended December 30, 2024. The company had until May 1, 2025, to request continued listing or suspension relief. The 1-for-85 reverse split on June 13, 2025, addressed the bid-price deficiency.

Financial and Strategic Analysis

As of July 31, 2025, Onconetix shares traded at $4.26, reflecting a 32.71% increase intraday, with a trading volume of 4,461,494 shares. Key trailing-twelve-month (TTM) metrics include:

• Revenue: $1.925 million
• Gross margin: 47.37%
• EBITDA: –$7.858 million
• Net margin: –2,914.75%
• EPS (TTM): –186,939.00
• Debt/equity ratio: 198.27%

The company’s market capitalization is approximately $1.675 million, with 521,900 shares outstanding, a 10-day average volume of 0.33 million, a beta of 3.35, and a year-to-date price change of –94.01%. An earnings release is scheduled for August 31, 2025.

Onconetix is focused on leveraging its FDA-approved ENTADFI therapy and Proclarix diagnostic to generate commercial revenues. The proposed transaction with Ocuvex is aimed at expanding its pipeline into ophthalmology and diversifying its product portfolio. The implementation of a reverse stock split serves to help maintain compliance with Nasdaq listing requirements.

Market Position and Industry Context

Prostate disease impacts nearly two-thirds of men over age 65, and the limitations of PSA testing increase the demand for more accurate diagnostic options. Proclarix is positioned to compete against established PSA assays and emerging biomarker platforms. ENTADFI addresses a significant market for BPH, which has traditionally been dominated by single-agent therapies; its combined formulation differentiates it from generic finasteride and branded tadalafil. As a micro-cap company with concentrated ownership and a high beta, Onconetix may encounter challenges related to liquidity and share-price volatility, but it also stands to gain from successful integration of complementary assets through the proposed Ocuvex agreement and the maintenance of its Nasdaq listing.

tl;dr

On June 13, 2025, Onconetix implemented a 1-for-85 reverse split to comply with Nasdaq’s $1.00 bid-price rule, resulting in 521,863 shares outstanding. Altos Venture AG holds 35.8% of the post-split equity. The company’s shares rose to $4.26 (up 32.71%) on July 31, 2025, with a market capitalization of $1.675 million. On April 8, 2025, Onconetix and Ocuvex Therapeutics signed a non-binding LOI to combine oncology and ophthalmic assets, pending due diligence and financing. Onconetix needs to file its delayed 2024 10-K or request listing relief by May 1, 2025. An earnings report is due on August 31, 2025.